Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile

Fidaxomicin (FDX), a narrow-spectrum antibiotic recently shown to be superior to vancomycin in providing sustained clinical response to Clostridium difficile infection, was investigated along with its major metabolite, OP-1118, with regard to their postantibiotic effects (PAE). FDX was found to have...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Babakhani, Farah, Gomez, Abraham, Robert, Nikki, Sears, Pamela
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2011
Konular:
Susceptibility
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3165303/
https://ncbi.nlm.nih.gov/pubmed/21709084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00104-11
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller